{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:21:47Z","timestamp":1783812107915,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000925","name":"John Templeton Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.omton.2025.200988","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T20:49:19Z","timestamp":1745959759000},"page":"200988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies"],"prefix":"10.1016","volume":"33","author":[{"given":"Nienke","family":"Visser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Gonz\u00e1lez-Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"\u00c1lvarez-Freile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurien G.","family":"Pruis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Rockstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm Jan","family":"Lourens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Jacob","family":"Schuringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0325-7376","authenticated-orcid":false,"given":"Edwin","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.200988_bib1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.omton.2025.200988_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric Antigen Receptors for T-Cell Malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.200988_bib3","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967376.35157.85","article-title":"S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA","volume":"7","author":"Pan","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.omton.2025.200988_bib4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12015-020-10092-9","article-title":"Treatment of Aggressive T Cell Lymphoblastic Lymphoma\/leukemia Using Anti-CD5 CAR T Cells","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.omton.2025.200988_bib5","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.3390\/ijms24087201","article-title":"An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia","volume":"24","author":"Patel","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2025.200988_bib6","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200988_bib7","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.bbmt.2018.12.145","article-title":"CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)","volume":"25","author":"Ramos","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2025.200988_bib8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13045-021-01178-z","article-title":"CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity","volume":"14","author":"Shi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.200988_bib9","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.ymthe.2024.09.006","article-title":"Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed\/refractory T-ALL: A phase I trial","volume":"33","author":"Zhao","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.200988_bib10","doi-asserted-by":"crossref","first-page":"CT052","DOI":"10.1158\/1538-7445.AM2020-CT052","article-title":"Abstract CT052: Clinical safety and efficacy study of TruUCAR\u2122 GC027: The first-in-human, universal CAR-T therapy for adult relapsed\/refractory T-cell acute lymphoblastic leukemia (r\/r T-ALL)","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200988_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2025.200988_bib12","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib13","series-title":"Atlas of Differential Diagnosis in Neoplastic Hematopathology","author":"Gorczyca","year":"2021"},{"key":"10.1016\/j.omton.2025.200988_bib14","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","article-title":"Stages of T-cell Receptor Protein Expression in T-cell Acute Lymphoblastic Leukemia","volume":"77","author":"Campana","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib15","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/intimm\/9.12.1875","article-title":"Targeted gene disruption of murine CD7","volume":"9","author":"Bonilla","year":"1997","journal-title":"Int. Immunol."},{"key":"10.1016\/j.omton.2025.200988_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1027318530127","article-title":"CD4+ CD7- T cells: a separate subpopulation of memory T cells?","volume":"17","author":"Reinhold","year":"1997","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.omton.2025.200988_bib18","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood.2021015020","article-title":"Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies","volume":"140","author":"Freiwan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.967754","article-title":"Chimeric antigen receptor T-cell therapy for T-ALL and AML","volume":"12","author":"Wei","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.200988_bib20","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2022-165822","article-title":"Development of an Off-the-Shelf Chimeric Antigen Receptor (CAR)-T Cell Therapy for T-Cell Acute Lymphoblastic Leukemia (T-ALL) without Gene Editing","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2025.200988_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.200988_bib23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.200988_bib24","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1073\/pnas.91.8.3127","article-title":"Domain swapping: entangling alliances between proteins","volume":"91","author":"Bennett","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.200988_bib25","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/pro.5560041202","article-title":"3D domain swapping: a mechanism for oligomer assembly","volume":"4","author":"Bennett","year":"1995","journal-title":"Protein Sci."},{"key":"10.1016\/j.omton.2025.200988_bib26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.200988_bib27","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1074\/jbc.275.5.3431","article-title":"Identification of CD7 as a Cognate of the Human K12 (SECTM1) Protein","volume":"275","author":"Lyman","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2025.200988_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10875-005-0356-5","article-title":"Expression of the CD7 Ligand K-12 in Human Thymic Epithelial Cells: Regulation by IFN-\u03b3","volume":"25","author":"Lam","year":"2005","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.omton.2025.200988_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","article-title":"Tuning the Ignition of CAR: Optimizing the Affinity of scFv to Improve CAR-T Therapy","volume":"79","author":"Duan","year":"2022","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.omton.2025.200988_bib30","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.200988_bib31","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-11-0303","article-title":"Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells","volume":"17","author":"De Bruyn","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200988_bib32","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/bloodadvances.2022008402","article-title":"SECTM1-based CAR T cells enriched with CD7-low\/negative subsets exhibit efficacy in CD7-positive malignancies","volume":"7","author":"Wei","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2025.200988_bib33","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin\u2019s Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.200988_bib34","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.omto.2022.02.013","article-title":"Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody","volume":"24","author":"Ye","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.200988_bib35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.200988_bib36","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200988_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.2019000940","article-title":"Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.200988_bib39","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.4049\/jimmunol.158.7.3259","article-title":"Construction and characterization of human CD7-specific single-chain Fv immunotoxins","volume":"158","author":"Pauza","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2025.200988_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2020-141249","article-title":"The Enhanced Functionality of Low-Affinity CD19 CAR T Cells Is Associated with Activation Priming and Polyfunctional Cytokine Phenotype","volume":"136","author":"Michelozzi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib41","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","article-title":"Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion","volume":"36","author":"Olson","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2025.200988_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008566","article-title":"Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity","volume":"12","author":"Shabaneh","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.200988_bib43","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200988_bib44","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1182\/blood-2022-169212","article-title":"Monitoring the in-Vivo Expansion and Persistence of CAR-T Cells As a Tool to Help Decision Making in Patients with Aggressive B-Cell Lymphoma","volume":"140","author":"F\u00fcrst","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib45","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1182\/blood-2024-204355","article-title":"Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed\/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study","volume":"144","author":"Li","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib46","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2018-99-119650","article-title":"CD19-CAR Therapy Using Naive\/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL","volume":"132","author":"Popplewell","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005701","article-title":"Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL","volume":"11","author":"Song","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.200988_bib48","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2021-145669","article-title":"Comparison of Efficacy and Safety Profile of Allogeneic Versus Autologous CD19 Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis","volume":"138","author":"Shahzad","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.200988_bib49","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia\/Lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200988_bib50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0145-2126(03)00180-2","article-title":"Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia","volume":"28","author":"Chang","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omton.2025.200988_bib51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.leukres.2006.06.001","article-title":"CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype","volume":"31","author":"Chang","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omton.2025.200988_bib52","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1158\/0008-5472.CAN-04-2756","article-title":"Target Cell\u2013Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor\u2013Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7","volume":"65","author":"Bremer","year":"2005","journal-title":"Cancer Res."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:05:01Z","timestamp":1762657501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2950329925000578"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.200988","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.200988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200988"}}